Otsuka Acquires Rights to Hematological Cancer Treatment Dacogen from Eisai

Otsuka has acquired rights from Eisai Inc. to develop and sell in the US, Canada and Japan the DNA methylation inhibitor Dacogen A .

http://ift.tt/1rWsjNN